Literature DB >> 28495914

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy.

Simone Claudiani1, Jane F Apperley2, Robert Peter Gale2, Richard Clark3, Richard Szydlo2, Simona Deplano2, Renuka Palanicawandar2, Jamshid Khorashad2, Letizia Foroni2, Dragana Milojkovic2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28495914      PMCID： PMC5541883          DOI： 10.3324/haematol.2017.168740

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.

Authors:  Markus Pfirrmann; Dobromira Evtimova; Susanne Saussele; Fausto Castagnetti; Francisco Cervantes; Jeroen Janssen; Verena S Hoffmann; Gabriele Gugliotta; Rüdiger Hehlmann; Andreas Hochhaus; Joerg Hasford; Michele Baccarani
Journal:  J Cancer Res Clin Oncol       Date:  2017-01-12       Impact factor: 4.553

2.  Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.

Authors:  Benjamin Hanfstein; Michael Lauseker; Rüdiger Hehlmann; Susanne Saussele; Philipp Erben; Christian Dietz; Alice Fabarius; Ulrike Proetel; Susanne Schnittger; Claudia Haferlach; Stefan W Krause; Jörg Schubert; Hermann Einsele; Mathias Hänel; Jolanta Dengler; Christiane Falge; Lothar Kanz; Andreas Neubauer; Michael Kneba; Frank Stegelmann; Michael Pfreundschuh; Cornelius F Waller; Karsten Spiekermann; Gabriela M Baerlocher; Markus Pfirrmann; Joerg Hasford; Wolf-Karsten Hofmann; Andreas Hochhaus; Martin C Müller
Journal:  Haematologica       Date:  2014-05-16       Impact factor: 9.941

3.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

4.  Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.

Authors:  R E Clark; I A Dodi; S C Hill; J R Lill; G Aubert; A R Macintyre; J Rojas; A Bourdon; P L Bonner; L Wang; S E Christmas; P J Travers; C S Creaser; R C Rees; J A Madrigal
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

5.  Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.

Authors:  Preetesh Jain; Hagop Kantarjian; Keyur P Patel; Graciela Nogueras Gonzalez; Rajyalakshmi Luthra; Rashmi Kanagal Shamanna; Koji Sasaki; Elias Jabbour; Carlos Guillermo Romo; Tapan M Kadia; Naveen Pemmaraju; Naval Daver; Gautam Borthakur; Zeev Estrov; Farhad Ravandi; Susan O'Brien; Jorge Cortes
Journal:  Blood       Date:  2016-01-04       Impact factor: 22.113

6.  Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.

Authors:  Claire M Lucas; Robert J Harris; Athina Giannoudis; Andrea Davies; Katy Knight; Sarah J Watmough; Lihui Wang; Richard E Clark
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

7.  Differences among young adults, adults and elderly chronic myeloid leukemia patients.

Authors:  F Castagnetti; G Gugliotta; M Baccarani; M Breccia; G Specchia; L Levato; E Abruzzese; G Rossi; A Iurlo; B Martino; P Pregno; F Stagno; A Cuneo; M Bonifacio; M Gobbi; D Russo; A Gozzini; M Tiribelli; A de Vivo; G Alimena; M Cavo; G Martinelli; F Pane; G Saglio; G Rosti
Journal:  Ann Oncol       Date:  2014-10-30       Impact factor: 32.976

Review 8.  Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

Authors:  N C P Cross; H E White; D Colomer; H Ehrencrona; L Foroni; E Gottardi; T Lange; T Lion; K Machova Polakova; S Dulucq; G Martinelli; E Oppliger Leibundgut; N Pallisgaard; G Barbany; T Sacha; R Talmaci; B Izzo; G Saglio; F Pane; M C Müller; A Hochhaus
Journal:  Leukemia       Date:  2015-02-05       Impact factor: 11.528

9.  Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.

Authors:  Naveen Pemmaraju; Hagop Kantarjian; Jianqin Shan; Elias Jabbour; Alfonso Quintas-Cardama; Srdan Verstovsek; Farhad Ravandi; William Wierda; Susan O'Brien; Jorge Cortes
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

Review 10.  Deep molecular responses for treatment-free remission in chronic myeloid leukemia.

Authors:  Stéphanie Dulucq; Francois-Xavier Mahon
Journal:  Cancer Med       Date:  2016-07-01       Impact factor: 4.452
View more
  15 in total

Review 1.  Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors.

Authors:  Michele Baccarani; Robert Peter Gale
Journal:  Leukemia       Date:  2021-05-17       Impact factor: 11.528

Review 2.  Early Management of CML.

Authors:  Naranie Shanmuganathan; Timothy P Hughes
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 3.  Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia.

Authors:  Massimo Breccia; Robin Foà
Journal:  Curr Oncol Rep       Date:  2018-03-06       Impact factor: 5.075

4.  Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.

Authors:  Sandrine Saugues; Céline Lambert; Elisabeth Daguenet; Hyacinthe Johnson Ansah; Ali Turhan; Françoise Huguet; Agnès Guerci-Bresler; Andreï Tchirkov; Dalil Hamroun; Eric Hermet; Bruno Pereira; Marc G Berger
Journal:  Ann Hematol       Date:  2022-08-30       Impact factor: 4.030

Review 5.  Treatment-free remission in patients with chronic myeloid leukaemia.

Authors:  David M Ross; Timothy P Hughes
Journal:  Nat Rev Clin Oncol       Date:  2020-05-06       Impact factor: 66.675

Review 6.  Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK.

Authors:  Nicholas C P Cross; Helen E White; Paul A S Evans; Jeremy Hancock; Mhairi Copland; Dragana Milojkovic; Joanne Mason; Sandra Craine; Adam J Mead
Journal:  Br J Haematol       Date:  2018-08-20       Impact factor: 6.998

7.  Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia.

Authors:  Graeme Greenfield; Ross McMullan; Nuala Robson; Julie McGimpsey; Mark Catherwood; Mary Frances McMullin
Journal:  BMC Hematol       Date:  2019-05-02

8.  MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia.

Authors:  Simone Claudiani; Aoife Gatenby; Richard Szydlo; George Nesr; Adi Shacham Abulafia; Renuka Palanicawandar; Georgios Nteliopoulos; Jamshid Khorashad; Letizia Foroni; Jane F Apperley; Dragana Milojkovic
Journal:  Haematologica       Date:  2019-03-28       Impact factor: 9.941

Review 9.  Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice.

Authors:  Richard E Clark
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 10.  Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid Leukemia.

Authors:  Matteo Molica; Elisabetta Abruzzese; Massimo Breccia
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-09-01       Impact factor: 2.576
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.